论文部分内容阅读
目的比较顺铂分别联合紫杉醇、诺维本、健择治疗晚期非小细胞肺癌的近期疗效和毒副反应。方法对61例非小肺癌患者应用顺铂分别联合国产紫杉醇、诺维本、健择静脉滴注治疗。结果TP(紫杉醇/顺铂)方案有效率45%,NP(诺维本/顺铂)方案有效率45%,GP(健择/顺铂)方案有效率47%。(3/4级)骨髓抑制发生率TP方案为27.2%,NP方案为40%,GP方案为31.5%。NP方案(3/4级)静脉炎发生率20%,TP方案(3/4级)发生率9%。结论3组比较,GP方案有效率略高。NP方案血液学毒性较重,静脉炎发生率较高,GP方案有较高肾毒性,TP方案周围神经炎发生率较高,而血液学毒性相对其他2组少。GP方案总的3/4级毒性相对低于其他方案,耐受性较好。
Objective To compare the short-term effects and side effects of cisplatin combined with paclitaxel, noviben and gemcitabine in the treatment of advanced non-small cell lung cancer. Methods Sixty-one patients with non-small lung cancer were treated with cisplatin combined with paclitaxel, noviben and gemcitabine respectively. Results The effective rate of TP (paclitaxel / cisplatin) was 45%, that of NP (noviben / cisplatin) was 45%, and that of GP (gemcitabine / cisplatin) was 47%. (Grade 3/4) The prevalence of myelosuppression was 27.2% for the TP regimen, 40% for the NP regimen, and 31.5% for the GP regimen. NP regimen (grade 3/4) had a 20% incidence of phlebitis and a 9% incidence of TP regimen (grade 3/4). Conclusion 3 groups, GP program efficiency slightly higher. NP program hematology toxicity, phlebitis a higher incidence of GP program has a higher nephrotoxicity, TP program higher incidence of peripheral neuritis, and hematological toxicity less than the other two groups. The total grade 3/4 toxicity of GP regimen is relatively lower than that of other regimens and the tolerability is better.